Unicycive Therapeutics (UNCY) Interest & Investment Income (2023 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Interest & Investment Income came in at $394000.0 in Q1 2026, up 74.34% YoY from $226000.0 in Q1 2025, and up 12.25% on a QoQ basis from $351000.0 in Q4 2025.
Unicycive Therapeutics (UNCY) Interest & Investment Income (2023 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 4 years of Interest & Investment Income data on file, last reported at $394000.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 74.34% year-over-year to $394000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 16.85% YoY) and the FY2025 annual result came in at $1.0 million, down 19.75% from the prior year.
- Interest & Investment Income improved to $394000.0 in Q1 2026, from $351000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $462000.0 in Q2 2024 to a low of $14000.0 in Q1 2023.
- A 4-year average of $252384.6 and a median of $234000.0 in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2024 — Interest & Investment Income surged 392.86% — and 2025, when it sank 66.45%.
- Tracing UNCY's Interest & Investment Income over 4 years: stood at $140000.0 in 2023, then soared by 124.29% to $314000.0 in 2024, then grew by 11.78% to $351000.0 in 2025, then rose by 12.25% to $394000.0 in 2026.
- The last three Interest & Investment Income figures came in at $394000.0 (Q1 2026), $351000.0 (Q4 2025), and $279000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | 441,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 441,000.00 |
| Mar 31, 2026 | 394,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Sep 30, 2025 | 279,000.00 |
| Jun 30, 2025 | 155,000.00 |
| Mar 31, 2025 | 226,000.00 |
| Dec 31, 2024 | 314,000.00 |
| Sep 30, 2024 | 416,000.00 |
| Jun 30, 2024 | 462,000.00 |
| Mar 31, 2024 | 69,000.00 |
| Dec 31, 2023 | 140,000.00 |
| Sep 30, 2023 | 227,000.00 |
| Jun 30, 2023 | 234,000.00 |
| Mar 31, 2023 | 14,000.00 |